Sun Pharma's Q2 profit falls 36% to ₹1,989 crore after a ₹1,269 crore one-time loss

What happened

• Sun Pharma reported consolidated net profit of ₹1,989 crore for the September 2026 quarter against ₹3,118 crore a year earlier, down 36%, on revenue from operations of ₹16,199 crore against ₹14,478 crore, up 12%, Upstox reported. Business Today gave the profit as ₹1,988.53 crore and said the quarter included a one-time loss of ₹1,269 crore, which it tied to US litigation and charges linked to the proposed acquisition of Organon.
• Upstox put EBITDA at ₹4,743 crore against ₹4,527 crore, up 5%, with the margin at 29.28% against 31.27%. Sales in the United States were $455 million, down 8.2% and about 27% of consolidated sales, and India sales rose 17.3% to ₹5,552 crore, 34.5% of the total. Business Today added global innovative medicines sales of $356 million, up 6.9%, and research spending of ₹778.4 crore, 4.8% of sales.
• The results were reported during the session, Upstox's article being timed at 2:46 PM and Business Today's at 3:06 PM. The shares closed at ₹1,800.60 against ₹1,761 on Thursday on Kite data, a rise of 2.25% by my calculation. Business Today linked the day's gain to the US drug regulator's approval of Ilumya for psoriatic arthritis and to progress on the Organon deal.

Why it matters

Good to know: A one-time loss is a charge a company books for a specific event, such as settling a lawsuit. It lowers reported profit for the quarter in which it is booked but is not expected to repeat every quarter.

Key facts

Consolidated net profit

₹1,989 crore (₹3,118 crore a year earlier), down 36%

Revenue from operations, per Upstox

₹16,199 crore (₹14,478 crore), up 12%

One-time loss, per Business Today

₹1,269 crore

EBITDA, per Upstox

₹4,743 crore (₹4,527 crore); margin 29.28% (31.27%)

US sales, per Upstox

$455 million, down 8.2%

Read the source

• Sun Pharmaceutical Q2 FY27 result: Net profit declines 36% YoY; US formulation sales falls to $455 millionUpstox
• Sun Pharma shares gain even as Q2 profit slips 36% YoY; here's whyBusiness Today

Sun Pharmaceutical Industries in the news before

1. 21 OCT 2026 · REGULATORYSun Pharma's Unloxcyt gets NCCN 2A preferred status for locally advanced skin cancer
2. 14 OCT 2026 · EVENING · CORPORATE ACTIONSSun Pharma's board approves up to ₹10,000 crore of debentures; a director resigns
3. 29 SEP 2026 · DEALS & FUNDINGSun Pharma licenses cholesterol drug lerodalcibep for markets outside the US and China